Japanese pharma giant Takeda (TYO: 4502) and Pfizer (NYSE: PFE) have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO).
The four-year analysis of the trial showed that Adcetris (brentuximab vedotin) combined with chemotherapy improved progression-free survival (PFS) and tolerability compared to a standard treatment in Europe.
This study involved patients with newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze